Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | The role of immunotherapy in smoldering myeloma

Malin Hultcrantz • 10 Dec 2023
ASH 2023
Multiple Myeloma Smoldering Myeloma Antibodies CAR-T Teclistamab

Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the role of immunotherapy in the treatment of smoldering myeloma, a precursor to active myeloma. She highlights the emerging roles of bispecific antibodies and CAR-T therapies, with specific potential being attributed to the monoclonal antibody teclistamab. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Malin Hultcrantz

0:53
Should patients with smoldering myeloma be treated outside of the clinical trial setting?
Malin Hultcrantz • 10 Dec 2023
2:26
Serum biomarkers as predictors of disease progression in smoldering myeloma
Malin Hultcrantz • 10 Dec 2023
1:38
Real-world safety and efficacy of belantamab mafodotin in R/R myeloma
Malin Hultcrantz • 28 Sep 2023
2:07
Changes in M-spike and FLC and the risk of progression in SMM
Malin Hultcrantz • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals